View:
United States securities and exchange commission logo
October 26, 2023
Frederick G. Vogt
Interim Chief Executive Officer
Iovance Biotherapeutics, Inc.
825 Industrial Road
Suite 400
San Carlos , California
Re: Iovance
Biotherapeutics, Inc.
Form 10-K for the
Fiscal Year Ended December 31, 2022
Filed February 28,
2023
File No. 001-36860
Dear Frederick G. Vogt:
We have limited our review of your filing to the financial
statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe
the comment applies to your facts and circumstances, please tell us why
in your response.
After reviewing your
response to this letter, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2022
Management's Discussion and Analysis of Financial Condition and Results
of Operations
Results of Operations for the Years Ended December 31, 2022 and 2021
Research and Development Expense, page 92
1. Please revise your
future filings to disclose your research and development costs incurred
for each of your key
product candidates, including, but not limited to lifileucel, for all
periods presented. To
the extent that you do not track expenses by product candidate,
program, or indication,
disclose that fact and explain why you do not maintain and
evaluate research and
development cost in this manner. For unallocated research and
development expenses,
provide a breakdown by type or nature of expense. Please
assure that the sum
reconciles to the total research and development expense for the
period on the
Consolidated Statements of Operations. Please provide us with your
proposed disclosure,
and tell us in which periodic report the proposed disclosure will be
included.
Frederick G. Vogt
Iovance Biotherapeutics, Inc.
October 26, 2023
Page 2
In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
Please contact Li Xiao at 202-551-4391 or Ibolya Ignat at 202-551-3636
with any
questions.
FirstName LastNameFrederick G. Vogt Sincerely,
Comapany NameIovance Biotherapeutics, Inc.
Division of
Corporation Finance
October 26, 2023 Page 2 Office of Life
Sciences
FirstName LastName